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infection (ie, in the gut or the environment) and it may 
be selected for by as many antimicrobials as there are 
resistance determinants in a given plasmid or transposon. 
The resistant strains may lead to superinfection; and 
dissemination of the resistance may occur by spread 
of the resistant strain, or by spread of the resistance 
determinants to other bacteria. Antibiotic combinations 
are unlikely to prevent this type of resistance and may 
even enhance the selection of resistant strains. Ihe 
likelihood of developing resistance during therapy 
depends upon the resistance mechanism and the genetic 
constitution of the infecting organism. Thus, acquisition 
of new resistance genes during therapy is quite unlikely. 
Mutation involving ribosomal binding sites of bacteria 
are selected with relatively high frequency in organisms 
with low copy number of ribosomal genes such as 
Helicobacterpylori and Mycobacterium tuberculosis and 
other mycobacteria. However, mutational resistance due 
to ribosomal binding site changes is much less likely in 
organisms such as staphylococci and enterococci which 
have a high copy number of ribosomal genes. 
The Enterococcus is a beautiful paradigm of an 
organism highly equipped to survive in the antibiotic 
era. Enterococci are intrinsically resistant to beta- 
lactams and have low-level intrinsic resistance to amino- 
glycosides and lincosamides. They have acquired 
resistance to virtually every other antibiotic (including 
newer agents such as quinupristimdalfopristin and 
even linezolid). Among the types of bacterial resistance 
acquired by the enterococci, none is more remarkable 
than its acquisition of resistance to vancomycin. In order 
to do this, the Enterococcus basically had to acquire 
genes that enabled it to synthesize unique cell wall 
precursors which would not bind vancomycin. Genes 
found in vancomycin-resistant enterococci are not native 
enterococcal genes, but likely have been acquired from 
a variety of cryptic anaerobes that are part of normal 
lIora and are difficult, if not impossible to identify by 
current cultural techniques. Resistance to penicillin 
in viridans streptococci is the result of mutations in 
penicillin-binding proteins that decrease affinity for 
penicillin. The fact that viridans streptococci could 
develop penicillin resistance in the presence of pressure 
from continuous heavy use of penicillin and other beta- 
lactams has been known since the 1970s when penicillin- 
resistant strains were noted to cause endocarditis in 
patients receiving continuous penicillin prophylaxis to 
prevent recurrence of rheumatic fever. The significance 
of resistance in viridans streptococci is enhanced by 
the fact that genes or portions of genes from viridans 
streptococci have clearly been transferred into pneumo- 
cocci and the resultant mosaic genes in pneumococci are 
the cause of penicillin resistance in this organism. 
Resistance to methicillin in staphylococci is related to 
the acquisition of a gene which encodes a penicillin- 
binding protein (PBP2) that has markedly decreased 
affinity for methicillin. The genetic control of this gene 
is complicated. More recently, strains of S. aureus with 
intermediate levels of resistance to glycopeptides have 
been described:, Although the exact mechanism of 
resistance in these strains is not known, it undoubtedly 
involves a series of mutations that ultimately decrease 
the effectiveness of penicillin-binding protein 4 and thus 
decrease cross linking of the cell wall. This results in 
uncrossed linked polymers which bind vancomycin or 
teicoplanin like a sponge. More recent studies have 
shown that virtually all of the GISA strains identified to 
date are of a similar agr type group (Group 2) and that 
these strains have mutations in agr function that alters 
their virulence and gives them enhanced ability to pro- 
duce biofilm and adhere to foreign substances. 
It is clear from the above that bacteria have a remark- 
able ability to develop resistance to antimicrobial agents. 
This leads to a continuous challenge to utilize antimicro- 
bial agents effectively and to look for antimicrobial 
agents active against new targets in resistant bacteria. 
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Cancer patients are prone to infections caused by 
Gram-positive cocci, in particular coagulase-negative 
staphylococci and viridans streptococci. This is due 
to the frequent long-term use of central venous 
catheters, severe mucosal damage from aggressive 
chemotherapy and the widely applied oral antimicrobial 
prophylaxis aimed at Gram-negative aerobic pathogens. 
As resistance to beta-lactam antibiotics among Gram- 
positive pathogens grew continuously over the past 
decade, clinicians relied increasingly on glycopeptides 
especially in neutropenic patients with malignancies-a 
patient population that is at increased risk for the 
development of resistant strains. Consequently, reports 
of vancomycin and teicoplanin resistance increased in 
both enterococci and staphylococci, making it necessary 
to reconsider the empiric use of glycopeptides and to 
evaluate new antimicrobial treatment strategies in these 
patients. 
Linezolid is the first oxazolidinone, a new synthetic 
class of antimicrobials, and is highly active against Gram- 
positive cocci including resistant strains. In a series of 
multinational, comparative clinical trials linezolid has 
been shown to be efficacious and safe in complicated skin 
and soft tissue infections, nosocomial pneumonia, and 
bacteremia.These data suggested that linezolid may serve 
as a useful addition to the therapeutic armamentarium 
for the treatment of infections in immunocompromised 
patients with malignancies. First results of studies in this 
patient group have shown promise. 
Smith et al* investigated the efficacy of iinezolid 
600 mg IV every 12 hours in 65 neutropenic patients 
(ANC < 1000) with serious infections. Inclusion criteria 
required the infection to be caused by aresistant Gram- 
positive organism that had not been treatable otherwise. 
These infections were primarily bacteremia (83%) with 
34% of these being catheter-related. In 87.7% of these 
patients, vancomycin-resistant Enterococcus fizecium 
was the causative organism, and vancomycin-resistant 
Enterococcus faecalis and methicillin-resistant Staphylo- 
coccus aureus were isolated in 3.1% and 6.2% of the 
patients, respectively. Linezolid achieved microbiological 
eradication in 83.3% of all evaluable patients with a 
mean time to eradication of 3.3 days. 
In an open-label, non-comparative compassionate 
use program, linezolid was given to patients with 
malignancies and to patients undergoing bone marrow 
transplantation (BMT) who developed a significant 
infection. Birmingham et al2 reported a 75.4% clinical 
cure and 82.3% microbiological cure of all evaluable 
patients with malignancies (n=122 and 50, respectively). 
In BMT patients receiving IV or oral linezolid, a clinical 
cure rate of 66.7% (n=24) and a microbiological cure 
rate of 66.6% were obtained.3 While the death rate was 
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expectedly high in this patient population, linezolid 
has been successful in treating infections in immuno- 
compromised patients and was well tolerated. 
Ongoing studies with linezolid further investigate its 
use in this patient group, and forthcoming data may 
provide additional situations in which linezolid would be 
an appropriate therapeutic choice. 
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The principal advantage of amphotericin B (AmB) over 
other antifungal compounds is the very broad spectrum 
of fungicidal activity. AmB is effective against a large 
range of organisms, including the majority of human 
pathogens and opportunistic pathogens - most Candida 
spp., Aspergillus ~fumigatus, Blastomyces dermatitidis, 
Coccidioides immitis, Cryptococcus neoformans, Histo- 
plasma capsulatum, and F’aracoccidioides brasiliensis. 
However, it is poorly active against Fusarium, certain 
Aspergillus and Trichosporon spp. 
Although the incidence of treatment emergent 
resistance is low, resistant strains of Cundida lusitaniae 
and C. tropicalis have occasionally been isolated.Accord- 
ing to the Infectious Diseases Society of America (IDSA) 
guidelines for the management of invasive fungal in- 
fections, amphotericin B deoxycholate (AmBd) remains 
the drug of choice for the treatment of aspergillosis, with 
an overall response rate ranging from 14% to 83% 
(mean 37%). It is commonly believed that AmBd 
should be given at peak recommended doses, 1 to 1.5 
mglkgid. Unfortunately, at this dosage this polyene drug 
is associated with significant toxicity, including infusion- 
related events, such as chills, fever, headache, nausea and 
vomiting, and dose-limiting nephrotoxicity. Although 
this is not an absolute indication to change treatment if 
kidney function is artificially supported, amphotericin B- 
induced renal impairment may necessitate premature or 
temporary withdrawal of treatment, or a reduction in 
the dose. Such measures may subsequently result in a 
worsening of the infection. AmBd-related side effects 
may also lead to increased costs due to prolonged 
hospitalization, use of dialysis and the need to administer 
premeditation. Ensuring adequate hydration (IV 
administration of 500 ml saline) prior to the initiation of 
treatment may reduce the severity of renal impairment. 
The optimal duration of therapy is unknown and depends 
on the severity of disease, the response to therapy, and 
the patient’s underlying disease(s) or immune status. 
Antifungal therapy should be continued through 
cancer chemotherapy, or restarted in patients who 
are expected to receive additional chemotherapy. The 
recently developed lipid formulations of AmB have 
provided new therapeutic opportunities for the treat- 
ment of aspergillosis, especially in patients with renal fail- 
ure or those who have failed therapy with amphotericin 
B. It is worthy to note that most lipid-based formulations 
are between 10 and 50 times more expensive than con- 
ventional formulations, although this evaluation does not 
